Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Immunotherapy and Immune Responses
TopicLeading institutions, researchers & key papers
This cluster of papers focuses on the immunobiology of dendritic cells, their role in antigen presentation, modulation of immunity, and their potential applications in cancer immunotherapy and vaccine development. The research covers topics such as dendritic cell subsets, tumor antigen presentation, immune tolerance, and the use of adjuvants to enhance immune responses.
589
Works
IDs:OpenAlex
How has Immunotherapy and Immune Responses's publication output changed over time?
ScholarIQpublication output · 1998–2020
Output declined67% over the shown period — from 3 works in 1998 to 1 in 2020.
3
1
1
1
1
1
1
1
2
1
1998200020042005200820102011201420172020
What are the most-cited papers on Immunotherapy and Immune Responses?
ScholarIQmost cited works
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
Steven A. Rosenberg, James Chih‐Hsin Yang, Douglas J. Schwartzentruber, Patrick Hwu, Francesco M. Marincola, Suzanne L. Topalian, Nicholas P. Restifo, Mark E. Dudley, Susan Schwarz, Paul J. Spiess, Maria R. Parkhurst, Yutaka Kawakami, Claudia A. Seipp, Jan Einhorn, Donald E. White
Nature Medicine. 19981,804 CitationsOPEN ACCESS
Induction of Protective IgA by Intestinal Dendritic Cells Carrying Commensal Bacteria
Andrew J. Macpherson, Therese Uhr
Science. 20041,577 Citations
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan, Rachel Rosenthal, Crispin T. Hiley, Andrew J. Rowan, Thomas B.K. Watkins, Gareth A. Wilson, Nicolai J. Birkbak, Selvaraju Veeriah, Peter Van Loo, Javier Herrero, Charles Swanton, Charles Swanton, Mariam Jamal‐Hanjani, Selvaraju Veeriah, Seema Shafi, Justyna Czyzewska-Khan, Diana Johnson, Joanne Laycock, Leticia Bosshard‐Carter, Rachel Rosenthal, Pat Gorman, Robert E. Hynds, Gareth A. Wilson, Nicolai J. Birkbak, Thomas B.K. Watkins, Nicholas McGranahan, Stuart Horswell, Richard Mitter, Mickael Escudero, Aengus Stewart, Peter Van Loo, Andrew Rowan, Hang Xu, Samra Turajlic, Crispin T. Hiley, Christopher Abbosh, Jacki Goldman, Richard Stone, Tamara Denner, Nik Matthews, Greg Elgar, Sophia Ward, Marta Costa, Sharmin Begum, Ben Phillimore, Tim Chambers, Emma Nye, Sofia Graca, Maise Al Bakir, Kroopa Joshi, Andrew J.S. Furness, Assma Ben Aïssa, Yien Ning Sophia Wong, Andy Georgiou, Sergio A. Quezada, John A. Hartley, Helen L. Lowe, Javier Herrero, David Lawrence, Martin Hayward, Nikolaos Panagiotopoulos, Shyam Kolvekar, Mary Falzon, Elaine Borg, Teresa Marafioti, Celia Simeon, Gemma Hector, Amy Smith, Marie Aranda, Marco Novelli, Dahmane Oukrif, Sam M. Janes, Ricky M. Thakrar, Martin Förster, Tanya Ahmad, Siow Ming Lee, Dionysis Papadatos-Pastos, Dawn Carnell, R. Mendes, Jeremy George, Neal Navani, Asia Ahmed, Magali N. Taylor, Junaid Choudhary, Yvonne Summers, Raffaele Califano, P. W. J. Taylor, Rajesh Shah, Piotr Krysiak, Kendadai Rammohan, Eustace Fontaine, Richard Booton, Matthew Evison, Philip Crosbie, Stuart Moss, Faiza Idries, Leena Dennis Joseph, Paul Bishop, Anshuman Chaturved, Anne Marie Quinn
S110447773. 20171,336 CitationsOPEN ACCESS
Activation of human dendritic cells through CD40 cross-linking.
Christophe Caux, Catherine Massacrier, Béatrice Vanbervliet, Bertrand Dubois, Cees van Kooten, Isabelle Durand, Jacques Banchereau
S22947807. 19941,331 CitationsOPEN ACCESS
Where is Immunotherapy and Immune Responses research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Immunotherapy and Immune Responses is open access?
ScholarIQopen access share
47%OPEN ACCESS
Gold
0%
Green
13%
Hybrid
7%
Bronze
27%
Closed
53%
Related on ScholarIQ
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Paper
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Paper
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Paper
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Paper
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Paper
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Paper